Brief: Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01
17/03/2026 10:19
March 17 (Reuters) - Greenwich Lifesciences Inc GLSI.O: GREENWICH LIFESCIENCES PROVIDES UPDATE SHOWING CONTINUED REDUCTION IN RECURRENCE RATE IN THE OPEN LABEL ARM OF FLAMINGO-01 GREENWICH LIFESCIENCES INC - REPORTS RECURRENCE RATE OF <1% PER YEAR IN NON-HLA-A*02 PATIENTS TREATED WITH GLSI-100 Source text: ID:nGNX650ZxP Further company coverage: GLSI.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio